Catalyst Calendar

Thu, Oct 1, 2026

1 updates

9:00 AM

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses

Presentation / Abstract • Phase 1/2Oral presentation Wed, Oct 7, 2026, 12:30 PM KSTlexeotx.com

Wed, Sep 23, 2026

1 updates

LXEO

7:00 AM

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum

lexeotx.com

Tue, Sep 22, 2026

1 updates

LXEO

7:00 AM

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated

lexeotx.com

Wed, Sep 2, 2026

1 updates

LXEO

7:00 AM

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in

lexeotx.com

Wed, Aug 12, 2026

1 updates

LXEO

7:00 AM

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment

Trial Start • Phase 3Trial initiation Mon, Jun 1, 2026lexeotx.com

Wed, Aug 5, 2026

1 updates

LXEO

7:00 AM

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc.

lexeotx.com